文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

软骨寡聚基质蛋白在多种癌症类型中作为一种分子生物标志物。

Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.

机构信息

Department of Gastroenterology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Department of Traditional Chinese Medicine, Second Military Medical University/Naval Medical University, Shanghai, China.

出版信息

Clin Transl Oncol. 2023 Feb;25(2):535-554. doi: 10.1007/s12094-022-02968-8. Epub 2022 Oct 18.


DOI:10.1007/s12094-022-02968-8
PMID:36255654
Abstract

PURPOSE: The main function of cartilage oligomeric matrix protein (COMP) is to maintain the synthesis and stability of the extracellular matrix by interacting with collagen. At present, there are relatively few studies on the role of this protein in tumors. This study aimed to explore the relationship between COMP and pan-cancer, and analyzed its diagnostic and prognostic value. METHODS: The Cancer Genome Atlas database, the Genotype-Tissue Expression database and the Cancer Cell Line Encyclopedia database was used for gene expression analysis. The receiver operating characteristic curve was used to assess the diagnostic value of COMP in pan-cancer. Kaplan-Meier plots were used to assess the relationship between COMP expression and prognosis of cancers. R software v4.1.1 was used for statistical analysis, and the ggplot2 package was used for visualization. RESULTS: COMP was significantly overexpressed in 15 human cancers and showed significantly difference in 12 molecular subtypes and 16 immune subtypes. In addition, the expression of COMP is associated with tumor immune evasion. The ROC curve showed that the expression of COMP could predict the occurrence of 16 kinds of tumors with relative accuracy, including adrenocortical carcinoma (ACC) (AUC = 0.737), breast invasive carcinoma (BRCA) (AUC = 0.896), colon adenocarcinoma (COAD) (AUC = 0.760), colon adenocarcinoma/rectum adenocarcinoma esophageal carcinoma (COADREAD) (AUC = 0.775), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) (AUC = 0.875), kidney renal papillary cell carcinoma (KIRP) (AUC = 0.773), kidney chromophobe (KICH) (AUC = 0.809), ovarian serous cystadenocarcinoma (OV) (AUC = 0.906), prostate adenocarcinoma (PRAD) (AUC = 0.721), pancreatic adenocarcinoma (PAAD) (AUC = 0.944), rectum adenocarcinoma (READ) (AUC = 0.792), skin cutaneous melanoma (SKCM) (AUC = 0.746), stomach adenocarcinoma (STAD) (AUC = 0.711), testicular germ cell tumors (TGCT) (AUC = 0.823), thymoma (THYM) (AUC = 0.777) and uterine carcinosarcoma (UCS) (AUC = 0.769). Furthermore, COMP expression was correlated with overall survival (OS), disease-specific survival (DSS) and progression-free interval (PFI) in ACC (OS, HR = 4.95, DSS, HR = 5.55, PFI, HR = 2.79), BLCA (OS, HR = 1.59, DSS, HR = 1.72, PFI, HR = 1.36), KIRC (OS, HR = 1.36, DSS, HR = 1.94, PFI, HR = 1.57) and COADREAD (OS, HR = 1.46, DSS, HR = 1.98, PFI, HR = 1.43). We selected previously unreported bladder urothelial carcinoma (BLCA) for further study and found that COMP could be an independent risk factor for OS, DSS and PFI. Moreover, we found differentially expressed genes of COMP in BLCA and obtained top 10 hub genes, including LGR4, LGR5, RSPO2, RSPO1, RSPO3, RNF43, ZNRF3, FYN, LYN and SYK. Finally, we verified the function of COMP at the cellular level by using J82 and T24 cells and found that knockdown of COMP could significantly inhibit migration and invasion. This finding supports that COMP could be a potential biomarker for pan-cancer diagnosis and prognosis encompassing tumor microenvironment, disease stage and prognosis. CONCLUSION: This finding supports that COMP could be a potential biomarker for pan-cancer diagnosis and prognosis encompassing tumor microenvironment, disease stage and prognosis.

摘要

目的:软骨寡聚基质蛋白(COMP)的主要功能是通过与胶原蛋白相互作用来维持细胞外基质的合成和稳定性。目前,关于这种蛋白质在肿瘤中的作用的研究相对较少。本研究旨在探讨 COMP 与泛癌的关系,并分析其诊断和预后价值。

方法:使用癌症基因组图谱数据库、基因组织表达数据库和癌症细胞系百科全书数据库进行基因表达分析。使用受试者工作特征曲线评估 COMP 在泛癌中的诊断价值。通过 Kaplan-Meier 图评估 COMP 表达与癌症预后的关系。使用 R 软件 v4.1.1 进行统计分析,并使用 ggplot2 包进行可视化。

结果:COMP 在 15 种人类癌症中显著过表达,在 12 种分子亚型和 16 种免疫亚型中存在显著差异。此外,COMP 的表达与肿瘤免疫逃逸有关。ROC 曲线显示,COMP 的表达可以相对准确地预测 16 种肿瘤的发生,包括肾上腺皮质癌(ACC)(AUC=0.737)、乳腺浸润性癌(BRCA)(AUC=0.896)、结肠腺癌(COAD)(AUC=0.760)、结肠腺癌/直肠腺癌食管癌(COADREAD)(AUC=0.775)、淋巴样肿瘤弥漫性大 B 细胞淋巴瘤(DLBC)(AUC=0.875)、肾肾乳头细胞癌(KIRP)(AUC=0.773)、肾嫌色细胞癌(KICH)(AUC=0.809)、卵巢浆液性囊腺癌(OV)(AUC=0.906)、前列腺腺癌(PRAD)(AUC=0.721)、胰腺腺癌(PAAD)(AUC=0.944)、直肠腺癌(READ)(AUC=0.792)、皮肤黑色素瘤(SKCM)(AUC=0.746)、胃腺癌(STAD)(AUC=0.711)、睾丸生殖细胞肿瘤(TGCT)(AUC=0.823)、胸腺瘤(THYM)(AUC=0.777)和子宫癌肉瘤(UCS)(AUC=0.769)。此外,COMP 表达与 ACC 的总生存期(OS)(HR=4.95)、疾病特异性生存期(DSS)(HR=5.55)和无进展间隔(PFI)(HR=2.79)、BLCA 的 OS(HR=1.59)、DSS(HR=1.72)和 PFI(HR=1.36)、KIRC 的 OS(HR=1.36)、DSS(HR=1.94)和 PFI(HR=1.57)和 COADREAD 的 OS(HR=1.46)、DSS(HR=1.98)和 PFI(HR=1.43)有关。我们选择了之前未报道的膀胱癌进行进一步研究,发现 COMP 可以作为 OS、DSS 和 PFI 的独立危险因素。此外,我们发现了 BLCA 中 COMP 的差异表达基因,并获得了前 10 个枢纽基因,包括 LGR4、LGR5、RSPO2、RSPO1、RSPO3、RNF43、ZNRF3、FYN、LYN 和 SYK。最后,我们使用 J82 和 T24 细胞在细胞水平上验证了 COMP 的功能,发现下调 COMP 可以显著抑制迁移和侵袭。这一发现支持 COMP 可能是一种潜在的泛癌诊断和预后生物标志物,涵盖肿瘤微环境、疾病阶段和预后。

结论:这一发现支持 COMP 可能是一种潜在的泛癌诊断和预后生物标志物,涵盖肿瘤微环境、疾病阶段和预后。

相似文献

[1]
Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.

Clin Transl Oncol. 2023-2

[2]
Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.

Comput Struct Biotechnol J. 2022-6-18

[3]
APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.

Neurol Res. 2024-3

[4]
Identifies microtubule-binding protein as a novel cancer biomarker associated with ferroptosis and tumor microenvironment.

Comput Struct Biotechnol J. 2022-6-24

[5]
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.

Front Immunol. 2021

[6]
PreMSIm: An R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer.

Comput Struct Biotechnol J. 2020-3-19

[7]
The molecular feature of macrophages in tumor immune microenvironment of glioma patients.

Comput Struct Biotechnol J. 2021-8-14

[8]
Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA.

RNA Biol. 2020-11

[9]
Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts.

Comput Struct Biotechnol J. 2022-1-7

[10]
Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.

Front Immunol. 2022

引用本文的文献

[1]
Osteoarthritis as a Systemic Disease Promoted Prostate Cancer In Vivo and In Vitro.

Int J Mol Sci. 2024-5-30

[2]
Serum proteomic profiling of precancerous gastric lesions and early gastric cancer reveals signatures associated with systemic inflammatory response and metaplastic differentiation.

Front Mol Biosci. 2024-3-22

[3]
The Potential of Extracellular Matrix- and Integrin Adhesion Complex-Related Molecules for Prostate Cancer Biomarker Discovery.

Biomedicines. 2023-12-28

[4]
C1QA and COMP: plasma-based biomarkers for early diagnosis of pancreatic neuroendocrine tumors.

Sci Rep. 2023-11-29

[5]
Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.

Front Immunol. 2023

[6]
Identification of the circRNA-miRNA-mRNA Regulatory Network in Pterygium-Associated Conjunctival Epithelium.

Biomed Res Int. 2022

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索